HRP20170814T1 - Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama - Google Patents
Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama Download PDFInfo
- Publication number
- HRP20170814T1 HRP20170814T1 HRP20170814TT HRP20170814T HRP20170814T1 HR P20170814 T1 HRP20170814 T1 HR P20170814T1 HR P20170814T T HRP20170814T T HR P20170814TT HR P20170814 T HRP20170814 T HR P20170814T HR P20170814 T1 HRP20170814 T1 HR P20170814T1
- Authority
- HR
- Croatia
- Prior art keywords
- glucocorticoid
- use according
- binding domain
- dose
- administered
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims 3
- 230000002411 adverse Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 claims 17
- 230000000926 neurological effect Effects 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 206010040026 Sensory disturbance Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 208000004209 confusion Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 206010013395 disorientation Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Developing Agents For Electrophotography (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Steroid Compounds (AREA)
Claims (13)
1. Glukokortikoid (GC) za uporabu u metodi amelioracije, liječenja ili profilakse neuroloških nuspojava uzrokovanih primjenom CD3 vezne domene, pri čemu se GC daje prije primjene prve doze CD3 vezne domene i prije primjene druge doze i/ili treće doze CD3 vezne domene.
2. Glukokortikoid za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedeni glukokortikoid deksametazon.
3. Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu se prva doza CD3 vezne domene primjenjuje u prvom vremenskom razdoblju i slijedom se druga doza CD3 vezne domene primjenjuje u drugom vremenskom razdoblju, pri čemu druga doza premašuje prvu dozu.
4. Glukokortikoid za uporabu iz patentnog zahtjeva 3, pri čemu se nakon prve i druge doze CD3 vezne domene tijekom prvog i drugog vremenskog razdoblja, primjenjuje treće doza CD3 vezne domene, pri čemu treća doza premašuje prvu i drugu dozu.
5. Glukokortikoid za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu se CD3 vezna domena primjenjuje neprekidno.
6. Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedeni neurološki nepoželjni događaj jedan ili više poremećaj osjeta, napadaji, encefalopatija, cerebralni edem, konfuzija, ataksija, apraksija, poremećaj govora, halucinacije, pareza, tremor, glavobolja ili disorjentacija.
7. Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu se glukokortikoid daje nakon pojave neurološke nuspojave.
8. Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedena CD3 vezna domena bispecifično jednolančano protutijelo.
9. Glukokoritkoid za uporabu u skladu s patentnim zahtjevom 8, pri čemu je navedeno bispecifično jednolančano protutijelo CD19 x CD3 bispecifično jednolančano protutijelo.
10. Glukokoritkoid za uporabu u skladu s patentnim zahtjevom 9, pri čemu je navedeno CD19 x CD3 bispecifično jednolančano protutijelo MT103.
11. Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedeni pacijent čovjek.
12. Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedeni pacijent karakteriziran omjerom B/T stanica manjim od 1:5.
13. Glukokortikoid za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 12 gdje se navedena CD3 vezna domena veže za ljudski CD3 epsilon.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41222910P | 2010-11-10 | 2010-11-10 | |
| PCT/EP2011/068862 WO2012062596A1 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
| EP11788077.3A EP2637670B2 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170814T1 true HRP20170814T1 (hr) | 2017-08-11 |
| HRP20170814T4 HRP20170814T4 (hr) | 2024-05-10 |
Family
ID=45044532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170814TT HRP20170814T4 (hr) | 2010-11-10 | 2011-10-27 | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10130638B2 (hr) |
| EP (3) | EP3228315B1 (hr) |
| JP (2) | JP6023717B2 (hr) |
| KR (1) | KR101891845B1 (hr) |
| CN (2) | CN103533943B (hr) |
| AU (3) | AU2011328393B2 (hr) |
| CA (1) | CA2816668C (hr) |
| CL (1) | CL2013001287A1 (hr) |
| CR (1) | CR20130278A (hr) |
| CY (1) | CY1118894T1 (hr) |
| DK (1) | DK2637670T4 (hr) |
| EA (1) | EA026075B1 (hr) |
| ES (2) | ES2627538T3 (hr) |
| FI (1) | FI2637670T4 (hr) |
| HR (1) | HRP20170814T4 (hr) |
| HU (1) | HUE032782T2 (hr) |
| IL (2) | IL226268B (hr) |
| LT (1) | LT2637670T (hr) |
| MA (1) | MA34726B1 (hr) |
| ME (1) | ME02722B (hr) |
| MY (1) | MY173177A (hr) |
| NZ (1) | NZ610034A (hr) |
| PL (1) | PL2637670T3 (hr) |
| PT (1) | PT2637670T (hr) |
| RS (1) | RS55995B2 (hr) |
| SG (2) | SG190174A1 (hr) |
| SI (1) | SI2637670T1 (hr) |
| TN (1) | TN2013000250A1 (hr) |
| UA (1) | UA113397C2 (hr) |
| WO (1) | WO2012062596A1 (hr) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5129122B2 (ja) | 2005-04-26 | 2013-01-23 | トリオン ファーマ ゲーエムベーハー | 癌治療のための抗体およびグルココルチコイドの組み合わせ |
| CA2816668C (en) | 2010-11-10 | 2021-03-23 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by cd3 specific binding domains |
| KR102147533B1 (ko) * | 2011-04-28 | 2020-08-25 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| KR102561553B1 (ko) * | 2013-03-15 | 2023-07-31 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| DK3083689T3 (da) | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
| UA119167C2 (uk) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Біспецифічне антитіло, яке зв'язується з cd38 та cd3 |
| CA2958479A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
| EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| AR102918A1 (es) | 2014-12-05 | 2017-04-05 | Genentech Inc | Anticuerpos anti-cd79b y métodos de uso |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| JP6871874B2 (ja) | 2015-06-16 | 2021-05-19 | ジェネンテック， インコーポレイテッド | ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法 |
| EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| CN106810611A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| CR20180418A (es) | 2016-02-03 | 2019-01-15 | Amgen Res Munich Gmbh | Contructos de anticuerpo biespecpificos para psma y cd3 que se ligan a células t |
| EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| MA46963A (fr) * | 2016-12-03 | 2019-10-09 | Juno Therapeutics Inc | Méthodes pour déterminer le dosage de céllules car-t |
| KR20180090600A (ko) | 2017-02-03 | 2018-08-13 | 주식회사 대유위니아 | 전기밥솥 |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質 |
| EP3676402B1 (en) * | 2017-08-30 | 2023-12-27 | Bristol-Myers Squibb Company | A method to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| MA51793A (fr) | 2018-02-08 | 2020-12-16 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
| CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| MX2022007158A (es) | 2019-12-13 | 2022-07-11 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso. |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
| WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| WO2023057650A1 (en) | 2021-10-10 | 2023-04-13 | Centre Hospitalier Universitaire Vaudois (Chuv) | A method for predicting side effects of drugs and vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| US20070224191A1 (en) | 2002-12-05 | 2007-09-27 | Pdl Biopharma, Inc. | Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies |
| EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| JP5129122B2 (ja) | 2005-04-26 | 2013-01-23 | トリオン ファーマ ゲーエムベーハー | 癌治療のための抗体およびグルココルチコイドの組み合わせ |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| CA2633594C (en) | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| NZ580755A (en) | 2007-04-03 | 2012-05-25 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| LT2982696T (lt) * | 2008-11-07 | 2019-06-10 | Amgen Research (Munich) Gmbh | Ūmios limfoblastinės leukemijos gydymas |
| ME02947B (me) * | 2009-10-27 | 2018-04-20 | Amgen Res Munich Gmbh | Režim doziranja kod primjene dvojno specifičnog protutijela cd19xcd3 |
| SG189869A1 (en) | 2010-10-27 | 2013-06-28 | Amgen Res Munich Gmbh | Means and methods for treating dlbcl |
| CA2816668C (en) | 2010-11-10 | 2021-03-23 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by cd3 specific binding domains |
-
2011
- 2011-10-27 CA CA2816668A patent/CA2816668C/en active Active
- 2011-10-27 LT LTEP11788077.3T patent/LT2637670T/lt unknown
- 2011-10-27 US US13/884,497 patent/US10130638B2/en active Active
- 2011-10-27 EP EP17159560.6A patent/EP3228315B1/en active Active
- 2011-10-27 SI SI201131196A patent/SI2637670T1/sl unknown
- 2011-10-27 ES ES11788077.3T patent/ES2627538T3/es active Active
- 2011-10-27 CN CN201180064622.5A patent/CN103533943B/zh active Active
- 2011-10-27 EP EP11788077.3A patent/EP2637670B2/en active Active
- 2011-10-27 PT PT117880773T patent/PT2637670T/pt unknown
- 2011-10-27 JP JP2013538125A patent/JP6023717B2/ja active Active
- 2011-10-27 FI FIEP11788077.3T patent/FI2637670T4/fi active
- 2011-10-27 CN CN201810044039.1A patent/CN108403702A/zh active Pending
- 2011-10-27 ES ES17159560T patent/ES2842937T3/es active Active
- 2011-10-27 UA UAA201307130A patent/UA113397C2/uk unknown
- 2011-10-27 AU AU2011328393A patent/AU2011328393B2/en active Active
- 2011-10-27 RS RS20170458A patent/RS55995B2/sr unknown
- 2011-10-27 HU HUE11788077A patent/HUE032782T2/en unknown
- 2011-10-27 SG SG2013034731A patent/SG190174A1/en unknown
- 2011-10-27 HR HRP20170814TT patent/HRP20170814T4/hr unknown
- 2011-10-27 ME MEP-2017-104A patent/ME02722B/me unknown
- 2011-10-27 MY MYPI2013001611A patent/MY173177A/en unknown
- 2011-10-27 KR KR1020137014669A patent/KR101891845B1/ko active IP Right Grant
- 2011-10-27 EA EA201390621A patent/EA026075B1/ru not_active IP Right Cessation
- 2011-10-27 EP EP20209362.1A patent/EP3831386A1/en active Pending
- 2011-10-27 SG SG10201508789TA patent/SG10201508789TA/en unknown
- 2011-10-27 PL PL11788077T patent/PL2637670T3/pl unknown
- 2011-10-27 WO PCT/EP2011/068862 patent/WO2012062596A1/en active Application Filing
- 2011-10-27 DK DK11788077.3T patent/DK2637670T4/da active
- 2011-10-27 NZ NZ610034A patent/NZ610034A/en unknown
-
2013
- 2013-05-09 CL CL2013001287A patent/CL2013001287A1/es unknown
- 2013-05-09 IL IL226268A patent/IL226268B/en active IP Right Grant
- 2013-06-10 TN TNP2013000250A patent/TN2013000250A1/fr unknown
- 2013-06-10 CR CR20130278A patent/CR20130278A/es unknown
- 2013-06-10 MA MA35999A patent/MA34726B1/fr unknown
-
2016
- 2016-07-06 JP JP2016133918A patent/JP6189491B2/ja active Active
-
2017
- 2017-03-29 AU AU2017202079A patent/AU2017202079B2/en active Active
- 2017-05-08 CY CY20171100491T patent/CY1118894T1/el unknown
-
2018
- 2018-01-25 IL IL257164A patent/IL257164B/en active IP Right Grant
- 2018-02-07 AU AU2018200915A patent/AU2018200915B2/en active Active
- 2018-10-11 US US16/157,985 patent/US11633408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170814T1 (hr) | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama | |
| JP2016193932A5 (hr) | ||
| HRP20201627T1 (hr) | Postupak liječenja s tradipitantom | |
| HRP20210902T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma | |
| BR112014028017A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| MX363350B (es) | COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES. | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
| WO2014080286A3 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| WO2012154975A3 (en) | Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion | |
| IN2015DN00370A (hr) | ||
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| MX2020011295A (es) | Tratamiento de dermatitis atopica. | |
| MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| EP4230197A3 (en) | High concentration medicant solutions for treating neurological disorders | |
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| AR092104A1 (es) | LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) | |
| MX2015016062A (es) | Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo. | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| NZ596015A (en) | Method and composition for the treatment of pain and/or inflammation | |
| MA35189B1 (fr) | Préparations, compositions pharmaceutiques et procédé de prévention et de traitement du processus de formation d'adhérences |